FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 663 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Woman Helps Students With Special Needs Achieve Success After Graduation December 23, 2021 Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line... May 18, 2026 FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with... December 9, 2022 PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for... March 28, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab EMA Recommends Extension of Indications for Talazoparib Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... Study Finds Light Therapy Helps Radiation-Related Skin Damage Heal 50% Faster
